Synthetic Adrenergic Agonists

Phenylephrine activates alpha-1 receptors on vascular smooth muscle, engaging the Gq/phospholipase C/IP3/calcium pathway to produce arteriolar and venous vasoconstriction. Systemic vascular resistance rises, blood pressure increases, and because there is no beta-1-mediated tachycardia to offset the baroreceptor response, the rise in arterial pressure triggers a compensatory reflex bradycardia through increased vagal tone. This reflex bradycardia is a defining clinical characteristic of phenylephrine and distinguishes it from norepinephrine, which also raises pressure but whose beta-1 activity partially blunts the baroreceptor response.

The absence of beta-1 activity is both an advantage and a limitation. The advantage: no arrhythmogenicity, no increase in myocardial oxygen demand. The limitation: phenylephrine cannot augment cardiac output, and in patients with already reduced cardiac output, the combination of increased afterload and reflex bradycardia can further reduce cardiac output. It should be avoided when low cardiac output is the primary hemodynamic problem.

Phenylephrine's pure alpha-1 profile makes it the vasopressor of choice in specific contexts. In spinal anesthesia-induced hypotension — one of the most common indications in obstetric anesthesia — phenylephrine is preferred because it raises maternal blood pressure without the tachycardia associated with ephedrine, and is associated with better fetal acid-base outcomes. Standard practice in obstetric spinal anesthesia is a prophylactic phenylephrine infusion initiated at the time of spinal injection.

Phenylephrine is also the preferred vasopressor in patients with hypertrophic obstructive cardiomyopathy who develop hypotension during anesthesia. In this condition, tachycardia and reduced afterload both worsen the dynamic outflow obstruction — phenylephrine raises afterload and allows reflex bradycardia, both of which reduce obstruction severity. Beta-1-stimulating agents are contraindicated in this setting.

Topical intranasal phenylephrine constricts nasal mucosal vessels via alpha-1 receptors, reliably reducing congestion. Oral phenylephrine at the marketed over-the-counter dose of 10 milligrams is not effective as a nasal decongestant — the drug undergoes extensive first-pass metabolism in the gut wall before reaching systemic circulation, resulting in plasma concentrations too low to produce nasal vasoconstriction. Topical and intranasal preparations bypass this problem and remain effective.

Ophthalmic phenylephrine drops (2.5% or 10%) produce mydriasis by contracting the iris dilator muscle via alpha-1 receptors. Unlike anticholinergic mydriatics such as tropicamide, phenylephrine does not cause cycloplegia — it dilates the pupil without impairing accommodation, because the ciliary muscle is controlled by muscarinic receptors, not alpha-1 receptors.

Beta-2 selectivity is relative, not absolute. At therapeutic inhaled doses, the selectivity is clinically meaningful. At high doses or when significant drug is absorbed systemically, all beta-2 selective agonists produce beta-1-mediated cardiac effects including tachycardia, increased contractility, and arrhythmias. The inhaled route limits systemic absorption and is therefore essential to the safety profile of this drug class — oral formulations of the same drugs produce substantially more cardiovascular adverse effects.

Albuterol is the prototype short-acting beta-2 agonist and the most widely used rescue bronchodilator worldwide. After inhalation, onset of bronchodilation occurs within 5 to 15 minutes, peak effect at 30 to 60 minutes, and duration of 4 to 6 hours. It is the first-line rescue medication for acute asthma symptoms and acute exacerbations of chronic obstructive pulmonary disease.

Systemic adverse effects at standard inhaled doses include skeletal muscle tremor (beta-2-mediated sodium-potassium-adenosine triphosphatase activation in skeletal muscle), tachycardia (from residual beta-1 activity and reflex response to vasodilation), and hypokalemia (intracellular potassium shift via sodium-potassium-adenosine triphosphatase). With high-dose nebulized albuterol used in severe acute asthma, these effects — particularly hypokalemia and tachycardia — can be clinically significant and require monitoring.

A critical prescribing rule: albuterol use more than twice per week for symptom relief indicates inadequate asthma control and signals the need for escalation to controller therapy, not simply more albuterol. Chronic overuse drives beta-2 receptor downregulation, reducing bronchodilatory response over time.

Long-acting beta-2 agonists provide 12 hours of bronchodilation per dose and are used for maintenance therapy in persistent asthma and chronic obstructive pulmonary disease. Salmeterol has a slow onset of 15 to 20 minutes — it cannot be used for acute rescue. Formoterol has a rapid onset of 1 to 3 minutes despite its 12-hour duration, which allows it to serve both maintenance and rescue functions in some clinical protocols.

The critical safety rule for long-acting beta-2 agonists in asthma: they must never be prescribed without an inhaled corticosteroid. The Salmeterol Multicenter Asthma Research Trial (SMART, 2006) found a small but statistically significant increase in asthma-related deaths in patients randomized to salmeterol without adequate inhaled corticosteroid coverage. The current standard of care is fixed-dose inhaled corticosteroid/long-acting beta-2 agonist combination inhalers for persistent asthma requiring maintenance therapy. In chronic obstructive pulmonary disease, where the inflammatory mechanism differs, long-acting beta-2 agonist monotherapy is approved and widely used.

Non-selective beta-blockers (propranolol, nadolol, carvedilol, timolol) block beta-2 receptors in airway smooth muscle, directly opposing the bronchodilatory effect of albuterol, salmeterol, and terbutaline. In a patient with asthma or reactive airway disease who is taking a non-selective beta-blocker, beta-2 agonist bronchodilators may be partially or completely ineffective during acute bronchospasm — a potentially life-threatening situation. This interaction requires either avoiding non-selective beta-blockers in patients with reactive airways (using cardioselective agents — metoprolol, atenolol — which have far less beta-2 blockade at standard doses) or accepting that very high doses of nebulized albuterol may be required to overcome the partial blockade.

This interaction is the same mechanism responsible for the failure of epinephrine to produce bronchodilation in anaphylaxis in patients on non-selective beta-blockers — the glucagon rescue strategy described in Module 2 applies in that context.

Beta-2 agonists lower serum potassium by activating the sodium-potassium-adenosine triphosphatase pump in skeletal muscle, shifting potassium intracellularly. Systemic corticosteroids — frequently co-administered during management of severe acute asthma — promote renal potassium excretion through their mineralocorticoid activity. When high-dose nebulized beta-2 agonists and systemic corticosteroids are used together in severe acute asthma, the hypokalemic effects are additive, potentially lowering serum potassium below 3.0 milliequivalents per liter. This degree of hypokalemia increases the risk of cardiac arrhythmias, particularly in patients with underlying cardiac disease. Serum potassium should be monitored during treatment of severe acute asthma and replaced as needed.

When a patient taking a monoamine oxidase inhibitor discontinues clonidine abruptly, the combination produces an amplified withdrawal crisis. Abrupt clonidine discontinuation already causes a norepinephrine surge through the upregulation-and-rebound mechanism described in Section 2. In a patient also taking a monoamine oxidase inhibitor, the enzymes responsible for catabolizing that norepinephrine surge are inhibited, so the excess norepinephrine persists far longer and at higher concentrations than in a patient without the inhibitor. The result is a substantially more severe and prolonged hypertensive crisis. This combination should generally be avoided; if both drugs are present, any dose reduction of clonidine must be gradual and performed under close monitoring.